Treatment with atorvastatin reduces serum adipocyte-fatty acid binding protein value in patients with hyperlipidaemia

European Journal of Clinical Investigation

Volumn 37, Issue 8, 2007, Pages 637-642

  Karpisek, M ^a   Stejskal, D ^b   Kotolova, H ^a   Kollar, P ^a   Janoutova, G ^c   Ochmanova, R ^b   Cizek, L ^c   Horakova, D ^c   Yahia, R Ben ^c   Lichnovska, R ^c   Janout, V ^c  

^a UNIVERSITY OF VETERINARY AND PHARMACEUTICAL SCIENCES   (Czech Republic)

^b Sternberk Hospital   (Czech Republic)

^c PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

A FABP; Atorvastatin; Cholesterol; Hyperlipidaemia; Metabolic syndrome; Treatment

Indexed keywords

ADIPOCYTE FATTY ACID BINDING PROTEIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CREATINE KINASE; FATTY ACID BINDING PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URIC ACID;

ADIPOCYTE; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD ANALYSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATINE KINASE BLOOD LEVEL; DOWN REGULATION; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL;

ADIPOCYTES; AGED; ANTICHOLESTEREMIC AGENTS; BODY MASS INDEX; CHOLESTEROL; FATTY ACID-BINDING PROTEINS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERLIPIDEMIAS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES;

EID: 34447308274     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2007.01835.x     Document Type: Article

References (30)

1. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004 173 : 309 14.
2. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard WJ et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation 1998 98 : 2513 9.
3. Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Peletidou A, Kleta D et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism 2005 54 : 1065 74.
4. Pontrelli L, Parris W, Adeli K, Cheung RC. Atorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism 2002 51 : 334 42.
5. Stalenhoef AF, Ballantyne CM, Sarti C, Murin J, Tonstad S, Rose H et al. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study. Eur Heart J 2005 26 : 2664 72.
6. Diabetes Atorvastin Lipid Intervention (DALI) Study Group. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia. Diabetes Care 2001 24 : 1335 41.
7. Armani A, Toth PP. The CARDS trial: diabetic patients dealt a winning hand. Curr Atheroscler Rep 2006 8 : 429 32.
8. Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther 2003 99 : 95 112.
9. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 2001 21 : 1712 9.
10. Ray KK, Cannon CP. Pathological changes in acute coronary syndromes. the role of statin therapy in the modulation of inflammation, endothelial function and coagulation. J Thromb Thrombolysis 2004 18 : 89 101.
11. Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005 16 : 624 9.
12. Staels B, Fruchart JC. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005 54 : 2460 70.
13. Ascer E, Bertolami MC, Venturinelli ML, Buccheri V, Souza J, Nicolau JC et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004 177 : 161 7.
14. Loboda A, Jazwa A, Jozkowicz A, Dorosz J, Balla J, Molema G et al. Atorvastatin prevents hypoxia-induced inhibition of endothelial nitric oxide synthase expression but does not affect heme oxygenase-1 in human microvascular endothelial cells. Atherosclerosis 2006 187 : 26 30.
15. Damcott CM, Moffett SP, Feingold E, Barmada MM, Marshall JA, Hamman RF et al. Genetic variation in fatty acid-binding protein-4 and peroxisome proliferator-activated receptor γ interactively influence insulin sensitivity and body composition in males. Metabolism 2004 53 : 303 9.
16. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF et al. Adipocyte fatty acid-binding protein, aP2, alters late atherosclerotic lesion formation in severe hypercholesterolemia. Arterioscler Thromb Vasc Biol 2002 22 : 1686 91.
17. Boord JB, Maeda K, Makowski L, Babaev VR, Fazio S, Linton MF et al. Combined adipocyte-macrophage fatty acid-binding protein deficiency improves metabolism, atherosclerosis, and survival in apolipoprotein E-deficient mice. Circulation 2004 110 : 1492 8.
18. Makowski L, Brittingham KC, Reynolds JM, Suttles J, Hotamisligil GS. The fatty acid-binding protein, aP2, coordinates macrophage cholesterol trafficking and inflammatory activity. J Biol Chem 2005 280 : 12888 95.
19. Xu A, Wang Y, Xu JY, Stejskal D, Tam S, Zhang J et al. Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem 2006 52 : 405 13.
20. Stejskal D, Karpisek M. Adipocyte fatty acid binding protein in a Caucasian population: a new marker of metabolic syndrome? Eur J Clin Invest 2006 36 : 621 5.
21. Llaverias G, Noe V, Penuelas S, Vazquez-Carrera M, Sanchez RM, Laguna JC et al. Atorvastatin reduces CD68, FABP4, and HBP expression in oxLDL-treated human macrophages. Biochem Biophys Res Commun 2004 318 : 265 74.
22. Grip O, Janciauskiene S, Lindgren S. Atorvastatin activates PPAR-gamma and attenuates the inflammatory response in human monocytes. Inflamm Res 2002 51 : 58 62.
23. Zelvyte I, Dominaitiene R, Crisby M, Janciauskiene S. Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res 2002 45 : 147 54.
24. Planavila A, Laguna JC, Vazquez-Carrera M. Atorvastatin improves peroxisome proliferator-activated receptor signaling in cardiac hypertrophy by preventing nuclear factor-κB activation. Biochim Biophys Acta 2005 1687 : 76 83.
25. Huptas S, Geiss HC, Otto C, Parhofer KG. Effect of atorvastatin (10 mg day-1) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol 2006 98 : 66 9.
26. Nakata M, Nagasaka S, Kusaka I, Matsuoka M, Ishibashi S, Yada T. Effect of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implicatons in glycaemic control. Diabetologia 2006 49 : 1881 92.
27. Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb 2006 13 : 123 9.
28. Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001 507 : 357 61.
29. Costa A, Casamitjana R, Casals E, Alvarez L, Morales J, Masramon X et al. Effects of atorvastatin on glucose homeostasis, postprandial triglyceride response and C-reactive protein in subjects with impaired fasting glucose. Diabet Med 2003 20 : 743 5.
30. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 1997 389 : 610 4.